Table 2.
Diagnostic procedures and susceptibility testing
| Characteristic | N | Percentage of total |
|---|---|---|
| Signs and symptoms of infectiona | ||
| Bleeding | 2 | 3.4% |
| Cough | 10 | 16.9% |
| Dyspnoea | 14 | 23.7% |
| Erythema | 4 | 6.8% |
| Fever | 33 | 55.9% |
| Gastrointestinal symptoms | 11 | 18.6% |
| Haemoptysis | 2 | 3.4% |
| Neurological signs | 8 | 13.6% |
| Pain | 35 | 59.3% |
| Tachypnoea | 2 | 3.4% |
| Other signs and symptomsb | 14 | 23.7% |
| Imaging proceduresa | ||
| CT head | 1 | 1.7% |
| CT paranasal sinuses | 4 | 6.8% |
| CT thorax | 10 | 16.9% |
| MRI head | 1 | 1.7% |
| Ultrasound heart | 4 | 6.8% |
| X-ray thorax | 5 | 8.5% |
| Mycological evidencea | ||
| Culture | 58 | 98.3% |
| Histology | 5 | 8.5% |
| Microscopy | 4 | 6.8% |
| Susceptibility testing | ||
| CLSI microdilution | 4 | 6.8% |
| Etest | 2 | 3.4% |
| EUCAST microdilution | 3 | 5.1% |
| Macrodilution method | 1 | 1.7% |
| Unknown | 11 | 16.9% |
| MIC (mg/L) by CLSI microdilution, median (IQR) | ||
| Amphotericin B | 1.5 (0.6-2.0) | |
| Caspofungin | 1.0 (1.0-8.0) | |
| Fluconazole | 10.0 (4.0-72.0) | |
| Flucytosine | 0.5 (0.5-0.5) | |
| Itraconazole | 0.8 (0.3-1.5) | |
| Ketoconazole | 2.0 (2.0-2.0) | |
| Miconazole | 32.0 (32.0-32.0) | |
| Posaconazole | 0.1 (0.1-0.1) | |
| Terbinafine | 1.0 (1.0-1.0) | |
| Voriconazole | 1.0 (1.0-1.0) | |
| MIC (mg/L) by concentration gradient diffusion assay, median (IQR) | ||
| Amphotericin B | 0.02 (0.01-0.03) | |
| Caspofungin | 8.5 (1.0-16.0) | |
| Itraconazole | 0.4 (0.1-0.6) | |
| Posaconazole | 0.03 (0.03-0.03) | |
| Voriconazole | 4.8 (1.5-8.0) | |
| MIC (mg/L) by EUCAST microdilution, median (IQR) | ||
| Amphotericin B | 0.1 (0.03-0.5) | |
| Anidulafungin | 0.001 (0.001-0.001) | |
| Caspofungin | 1.1 (0.1-2.0) | |
| Flucytosine | 0.1 (0.1-0.1) | |
| Itraconazole | 0.05 (0.03-0.1) | |
| Posaconazole | 0.03 (0.03-0.03) | |
| Voriconazole | 1.0 (0.3-8.0) | |
MRI, magnetic resonance imaging.
a
Data may be superadditive.
b
Other signs and symptoms included haematuria (n = 3), malaise (n = 3), nasal congestion (n = 1), otorrhoea (n = 1), rhinorrhoea (n = 1), signs of heart failure (n = 2), and weight loss (n = 3).